论文部分内容阅读
目的:观察芪麦口服液对高脂血症大鼠高密度脂蛋白胆固醇(HDL)及超敏C-反应蛋白(hsCRP)表达的影响。方法:将Wistar大鼠随机分为模型组、阳性对照组及芪麦口服液低剂量组、芪麦口服液高剂量组,每组各10只。各组大鼠均腹腔注射70万U/kg维生素D3,连续3 d之后,喂饲高脂饲料21 d建立高脂大鼠模型。芪麦口服液低、高剂量组在造模的同时分别以0.935、3.760 mg·g-1·d-1的药量进行灌胃,阳性对照组以阿托伐他汀片0.002 mg·g-1·d-1进行灌胃。分别于造模前及用药后1周、2周、3周检测大鼠血清中HDL和hs-CRP的含量。结果:造模后各组均随高脂饲料的持续给予,血清中HDL水平逐渐下降、hs-CRP水平逐渐增高。各药物干预组灌胃1周时血清HDL水平与模型组无明显差异(P>0.05),而连续干预2周和3周时HDL水平的下降趋势均较模型组得到明显缓解(P<0.05或P<0.01);除芪麦口服液低剂量组灌胃1周时大鼠血清hs-CRP水平与模型组无明显差异(P>0.05)外,其余各药物干预组及各时间点均可显著抑制hs-CRP水平的增高(P<0.05或P<0.01)。其中,芪麦高剂量组总体优于低剂量组,并与阳性药物组作用相当。结论:芪麦口服液能够有效调节动脉粥样硬化大鼠高密度脂蛋白水平,抑制超敏C-反应蛋白的血清水平表达。
Objective: To observe the effect of Qimai Oral Liquid on the expression of high density lipoprotein cholesterol (HDL) and high sensitivity C-reactive protein (hsCRP) in hyperlipidemic rats. Methods: Wistar rats were randomly divided into model group, positive control group and Qimai oral liquid low dose group and Qimai oral liquid high dose group, 10 rats in each group. All rats were intraperitoneal injection of 700000 U / kg vitamin D3, 3 consecutive days, high-fat diet fed 21 days to establish a model of high-fat rats. Astragalus oral liquid low and high dose groups were given gavage at 0.935 and 3.760 mg · g-1 · d-1, respectively. The positive control group received atorvastatin tablets 0.002 mg · g-1 · D-1 for gavage. The contents of HDL and hs-CRP in the serum of rats were measured before model and 1 week, 2 weeks and 3 weeks after treatment. Results: After modeling, the rats in each group continued to receive high-fat diet, the level of serum HDL gradually decreased and the level of hs-CRP gradually increased. Compared with model group, serum HDL levels in each drug intervention group had no significant difference (P> 0.05) at 1 week, while HDL levels in continuous intervention group at 2 weeks and 3 weeks decreased significantly (P <0.05 or P <0.01). The serum hs-CRP levels in the low-dose QHD group were not significantly different from those in the model group (P> 0.05), and the other drug intervention groups and the time points were significant Inhibit the increase of hs-CRP level (P <0.05 or P <0.01). Among them, Qimai high-dose group overall better than the low-dose group, and the role of the positive drug group. Conclusion: Qimai Oral Liquid can effectively regulate high density lipoprotein and inhibit the serum level of hypersensitive C-reactive protein in atherosclerosis rats.